title: [A Case of Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Treated with TAS-102 with Bevacizumab].
abstract: A 51-year-oldwoman with lung, liver, andd istant lymph node metastases from sigmoidcolon cancer was treatedusing TAS-102 with bevacizumab as fourth-line chemotherapy. There was a 35%decrease in the size of target lesions after the first 4 cycles of therapy, and disease control has been maintained for 9 months. The only Grade 3 or worse adverse event experiencedwas neutropenia. In patients with refractory colorectal cancer, the combination of TAS-102 with bevacizumab might be an effective andsafe treatment.
authors.affiliation: Dept. of Surgery, Osaka Rosai Hospital.
authors.forename: Junichi
authors.initials: J
authors.lastname: Hasegawa
authors.forename: Shingo
authors.initials: S
authors.lastname: Noura
authors.forename: Masaki
authors.initials: M
authors.lastname: Hirota
authors.forename: Tae
authors.initials: T
authors.lastname: Matsumura
authors.forename: Akinobu
authors.initials: A
authors.lastname: Yasuyama
authors.forename: Akihiro
authors.initials: A
authors.lastname: Takata
authors.forename: Chikato
authors.initials: C
authors.lastname: Koga
authors.forename: Masahiro
authors.initials: M
authors.lastname: Murakami
authors.forename: Chizu
authors.initials: C
authors.lastname: Kameda
authors.forename: Naofumi
authors.initials: N
authors.lastname: Oda
authors.forename: Ryohei
authors.initials: R
authors.lastname: Kawabata
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Morishima
authors.forename: Junzo
authors.initials: J
authors.lastname: Shimizu
authors.forename: Nobuki
authors.initials: N
authors.lastname: Matsunami
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011759:Pyrrolidines; D012811:Sigmoid Neoplasms / Q000188:drug therapy* / Q000601:surgery; D013941:Thymine; D016896:Treatment Outcome; D014271:Trifluridine / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D004338:Drug Combinations; D011759:Pyrrolidines; C000613803:trifluridine tipiracil drug combination; D000068258:Bevacizumab; D014498:Uracil; D013941:Thymine; D014271:Trifluridine